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1 Introduction
Human protein C (hPC) is a vitamin K-dependent plasma 
glycoprotein having anti-coagulant activity, and circulates 
primarily as a disulfide-linked heterodimer composed of a 
light chain (25 kDa) and heavy chain (41 kDa) [1, 2]. Prior to 
secretion, hPC undergoes extensive PTM, including γ-car-
boxylation of nine Glu residues, β-hydroxylation of Asn-71, 
proteolytic maturation (propeptide and internal dipeptide 
removal), and N-glycosylation at up to four Asn residues 
[3, 4]. The potential N-glycosylation sites are in the epider-
mal growth factor (EGF) domain of the light chain at Asn-
97 and in the heavy chain at Asn-248, 313, and 329. 
The N-glycosylation site at Asn-329 contains the unusual 
sequon Asn-X-Cys (X is any amino acid except Pro) that is 
also found in bovine protein C [5]. The hPC has been re-
ported to be 70–80% glycosylated at this sequon by SDS-
PAGE analysis, and bovine protein C is reported to be fully 
glycosylated [5–8]. The N-glycosylation of the atypical Asn-
X-Cys sequon has been characterized in the literature for 
only six other proteins: human alpha1T-glycoprotein, human 
von Willebrand factor, human CD69, human alpha-lactalbu-
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Abstract
Human protein C (hPC) is glycosylated at three Asn-X-Ser/Thr and one atypical Asn-X-Cys sequons. We have character-
ized the micro- and macro-heterogeneity of plasma-derived hPC and compared the glycosylation features with recombi-
nant protein C (tg-PC) produced in a transgenic pig bioreactor from two animals having approximately tenfold different 
expression levels. The N-glycans of hPC are complex di- and tri-sialylated structures, and we measured 78% site occupancy 
at Asn-329 (the Asn-X-Cys sequon). The N-glycans of tg-PC are complex sialylated structures, but less branched and par-
tially sialylated. The porcine mammary epithelial cells glycosylate the Asn-X-Cys sequon with a similar efficiency as human 
hepatocytes even at these high expression levels, and site occupancy at this sequon was not affected by expression level. A 
distinct bias for particular structures was present at each of the four glycosylation sites for both hPC and tg-PC. Interest-
ingly, glycans with GalNAc in the antennae were predominant at the Asn-329 site. The N-glycan structures found for tg-PC 
are very similar to those reported for a recombinant Factor IX produced in transgenic pig milk, and similar to the endoge-
nous milk protein lactoferrin, which may indicate that N-glycan processing in the porcine mammary epithelial cells is more 
uniform than in other tissues.
Keywords: Asn-X-Cys, glycosylation, mass spectrometry, N-glycan, protein C
Abbreviations: 2-AA, 2-aminobenzoic acid; GluC, glutamyl endopeptidase; hPC, human protein C (plasma-derived); 
LysC, lysyl endopeptidase; MRM, multiple reaction monitoring; Neu5Ac, Nacetylneuraminic acid; Neu5Gc, N-glycolyl-
neuraminic acid; NP, normal phase; tg-PC, transgenic pig-derived human protein C
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min, murine and human fetal antigen 1, and recombinant 
human epidermal growth factor receptor [9–15]. In these 
proteins, the reported site occupancy at this sequon ranged 
from sparse (1% in alpha-lactalbumin) to full (von Wille-
brand factor, and human fetal antigen 1) [15]. Where glycan 
structures are reported for these sequons, they are complex 
bi- and tri-antennary with and without both sialylation and 
fucosylation. The N-glycans of hPC are important to func-
tion, and Grinnell et al. [7] showed by site-directed mutagen-
esis that the N-glycosylation of hPC affects protein secre-
tion, protein folding and subsequent glycosylation at other 
sequons, proteolytic processing, and anticoagulant activity. 
Although N-glycosylation is an important factor for hPC bi-
ological functionality, there are no published reports of the 
N-glycan structures found in plasma-derived hPC, or of the 
glycosylation micro-heterogeneity at the four sites, espe-
cially with respect to the unusual sequon at Asn-329. 
Several host systems have been employed to produce 
recombinant hPC. Recombinant activated PC (Drotrecogin 
alfa™ or Xigris) is produced in human kidney 293 cell cul-
ture by Eli Lilly for the treatment of sepsis [16–18], and the 
N-glycan structures of hPC produced in these cells have 
been published [19]. Transgenic animal bioreactors are an 
alternative mammalian expression system that can be used 
to produce recombinant glycoproteins [20]. Biologically ac-
tive recombinant hPC has been produced in the transgenic 
pig mammary gland (tg-PC) at different expression levels 
[21, 22]. However, the N-glycan structures and the micro- 
and macro-heterogeneity, especially with respect to Asn-
329, have not been reported.
In this work, we characterize the N-glycan structures 
and the micro- and macro-heterogeneity of hPC and tg-PC 
with a special emphasis on the atypical Asn329-X-Cys se-
quon. We discuss the characteristics of the N-glycosylation 
of hPC and tg-PC with the intent to contribute towards an 
improved understanding of the differences and similarities 
between N-glycan processing in human hepatocytes ver-
sus transgenic animal mammary epithelial cells. Addition-
ally, we investigate if there is evidence for rate limitations 
in the N-glycan attachment and processing in the porcine 
mammary gland by comparing two transgenic lineages 
having up to tenfold different expression levels. We also 
compare N-glycosylation of tg-PC with another recombi-
nant vitamin K-dependent glycoprotein that has been pro-
duced in the transgenic pig mammary gland, Factor IX (tg-
FIX) [23], and discuss the features of N-glycan processing 
of recombinant proteins that are evident in the transgenic 
pig bioreactor.
2 Materials and methods
2.1 Materials
Plasma-derived human protein C (hPC) was purchased 
from Enzyme Research Laboratories (South Bend, IN). 
PNGase F was purchased from New England Biolabs (Bev-
erly, MA). Glutamyl endopeptidase (GluC) and triethyl-
amine were purchased from EMD Chemicals (Gibbstown, 
NJ), and Lysyl endopeptidase (LysC) was purchased from 
Waco (Japan). Isotopically labeled standard peptides were 
custom synthesized by AnaSpec (San Jose, CA). Tetrahy-
drofuran (0.025% BHT inhibited) was purchased from J. T. 
Baker (Phillipsburg, NJ), and DTT, iodoacetamide, and all 
other chemicals were obtained from Sigma (St. Louis, MO).
2.2 Purification of transgenic hPC from pig milk
DEAE Sepharose FF (Amersham Biosciences, Piscataway, 
NJ) was packed in a Poros HP glass column (10 mm ID × 
92 mm L, PerSeptive Biosystems, Framingham, MA). A 
BioCAD Vision chromatography system (Applied Biosys-
tems, Foster City, CA) was used with 280 nm detection. 
Daily milk samples from days 5–40 were pooled together 
and mixed 1:1 v/v with 200 mM EDTA pH 7.4 and then 
centrifuged for 30 min at 12,000 rpm at 4°C. The solidified 
milk fat was removed and then diluted 1:5 v/v with load-
ing buffer (20 mM Tris, 50 mM NaCl, 0.1% Tween 20, pH 
7.4), and loaded onto the column at 0.5 cm/min. The col-
umn was washed with loading buffer at 3 cm/min. Tg-
PC was eluted with 20 mM Tris, 250 mM NaCl, pH 7.4 at 
3 cm/min. The column was washed with 20 mM Tris, 4 M 
NaCl, pH 7.4 and then cleaned with 1 M NaOH at 3 cm/
min. The purified tg-PC was further purified by an immu-
noaffinity column. 12A8 monoclonal anti-hPC (a gift from 
the American Red Cross, Rockville, MD) was coupled onto 
HiTrap NHS-activated Sepharose (16 mm ID × 25 mm L, 
Amersham Biosciences, Piscataway, NJ) as described in the 
product manual. Briefly, the column was washed with ice-
cold 1 mM HCl. The antibody was dissolved in coupling 
buffer (0.2 M NaHCO3, 0.5 M NaCl, pH 8.3) and loaded 
onto the column. The column was sealed and incubated for 
12 h at 4°C, then washed with washing buffer A (0.5 Meth-
anolamine, 0.5 M NaCl, pH 8.3), followed by washing buf-
fer B (0.1 M acetate, 0.5 M NaCl, pH 4). Uncoupled sites on 
the column were blocked with buffer A for 4 h at 4°C. Then 
the column was washed with washing buffer A and B, and 
equilibrated with 20 mM Tris, 250 mM NaCl, pH 7.4. The 
product from the DEAE column was loaded onto the affin-
ity column at 1 cm/min. After washing with 20 mM Tris, 
250 mM NaCl, pH 7.4 at 1 cm/min, tg-PC was eluted with 
0.1 M Na2CO3, 0.15 M NaCl, pH 10. The affinity column 
was cleaned with 2 M NaSCN, followed by 4 M NaCl.
2.3 Sialic acid analysis using RP-HPLC
Sialic acids were analyzed by RP-HPLC using the method 
described in Anumula et al. (1995) [24]. Protein C sam-
ples (5–10 μg in 50 μL) were mixed with 50 μL of 0.5 M so-
dium bisulfate (NaHSO4) in 1.6 mL screw cap microcentri-
fuge tubes, and then hydrolyzed at 80°C for 20 min. The 
hydrolyzed samples were derivatized by adding 100 μL 
of o-phenyllenediamine-2HCl, OPD (20 mg/mL in 0.25 M 
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NaHSO4). The tubes were heated at 80°C for 40 min. Sol-
vent A consisted of 0.15% v/v 1-butylamine, 0.5% v/
v phosphoric acid, and 1% v/v tetrahydrofuran in wa-
ter. Solvent B was 50% of solvent A in ACN. After cool-
ing the samples down to room temperature, 0.8 mL of sol-
vent A was added and vortexed vigorously. Proteins and 
any other particles were precipitated by centrifugation and 
the supernatant (100 μL) was analyzed by RP-HPLC (Su-
pelcosil LC318 HPLC column; 4.6 mm id × 250 mm L, 5 μm 
particles, Supelco, St. Louis, MO). The column was equil-
ibrated with 5% B for 10 min. The OPD-derivatized sialic 
acids were eluted with 13% B for 20 min and the column 
was washed for 10 min with 100% solvent B. A Waters 2695 
Separations module and 2475 fluorescence detector (Mil-
ford, MA) were used to detect OPD-derivatized sialic acids. 
The detector settings were 230 nm excitation, 425 nm emis-
sion, and 40 nm bandwidth. The sialic acid standard mix-
ture (Neu5Ac and Neu5Gc) were also analyzed each time 
with the analysis of glycoproteins. Calibration curves were 
determined with 6 different levels of each sialic acid stan-
dard (100, 200, 400, 600, 800, and 1000 pmol). Linearity of 
the calibration curves was accepted if the correlation coef-
ficient (R2) was greater than 0.99. Empower software (Wa-
ters) was used to integrate peak areas and construct the cal-
ibration curves. Protein C concentrations were determined 
by measuring OD280nm (extinction coefficient of 1.45 mL/
mg-cm) [1]. The sialic acid to protein ratio (mol/mol) was 
calculated by obtained moles of sialic acid divided by pro-
tein moles injected.
2.4 PNGase F digestion and purification of N-glycans from 
protein C
Protein C samples were incubated with PNGase F (sub-
strate: enzyme = 250:1 mass ratio) in 50 mM sodium phos-
phate at 37°C for 24 h. Released N-glycans were separated 
from protein using C18 Extract Clean columns (100 mg, 
1.5 mL Alltech, Deerfield, IL). The cartridges were equil-
ibrated with 6 mL of 5% acetic acid in water. Then, the 
sample was applied to the column. The flow through, 
along with the wash of 1 mL of 5% acetic acid, contained 
the N-glycans. 
The N-glycan fraction was further desalted by using 
Carbograph Extract Clean columns (150 mg, 4 mL, Alltech). 
The solvent system was as follows: A, 0.1% TFA w/v in 
50% ACN/50% water, B, 0.1% TFA w/v in 5% ACN/95% 
water. The cartridge was washed with 30% acetic acid in 
water first and then HPLC grade water, and primed with 3 
mL of solvent A followed by 6 mL of solvent B. The glycan 
solution was applied to the column, and then washed with 
water and solvent B. Glycans were eluted with 2 × 0.5 mL 
of solvent A, and dried by speed-vac.
For MS analysis, the glycan samples were further puri-
fied by Stylus Protip 5–50 μL HILIC (Hydrophilic Interac-
tion Chromatography) needle (The Nest Group, Southboro, 
MA). The dried glycan was dissolved in 50 μL of 90% ACN 
and then aspirated in and out of the tip to allow maximum 
binding to the media. The adsorbed sample was washed 
with 90% ACN. Glycans were eluted with 50 μL of water.
2.5 Derivatization of N-glycan with 2-aminobenzoic acid
N-glycan profiles were determined based on the HPLC 
method of Anumula and Dhume (1998) [25], where oligo-
saccharides can be separated based on size, charge, link-
age, and overall structure. Dried N-glycans released by 
PNGase F digestion were reconstituted with 100 μL wa-
ter prior to derivatization. The derivatization reagent was 
prepared fresh by dissolving 30 mg of 2-aminobenzoic 
acid (2-AA) and 20 mg of sodium cyanoborohydride in 1 
mL of 4% sodium acetate trihydrate w/v and 2% boric acid 
w/v in methanol. Purified N-glycans (20 μL) were mixed 
with 100 μL of the derivatization reagent in 1.5 mL screw 
cap centrifuge tubes, and then reacted at 80°C for 40 min. 
After cooling, the sample was diluted with 1 mL 95% v/v 
ACN/water. Excess reagent was removed by Waters Oa-
sis HLB cartridge (1 mL, Milford, MA). The cartridge was 
rinsed with 2 mL of 95% v/v ACN/water. The sample was 
applied to the cartridge, followed by washing with 2 mL 
of 95% v/v) ACN/water. The AA-derivatized N-glycans 
were eluted by 1 mL of 20% v/v ACN/water. The eluted 
N-glycans were stored at –80°C for normal phase (NP)-
HPLC profiling analysis.
2.6 NP-HPLC profiling of AA-derivatized N-glycan
Profiling of AA-derivatized N-glycan was performed on an 
amine-bonded polymeric column (Polymer-NH2, 5μm, 4.6 
mm id × 250 mm L, Astec, Whippany, NJ) with a CPF10 
prefilter (Vydac, Hesperia, CA). Solvent A was 2% acetic 
acid and 1% tetrahydrofuran (inhibited) in ACN, and Sol-
vent B was 5% acetic acid, 3% triethylamine and 1% tetra-
hydrofuran (inhibited) in water. The derivatized sample 
(100 μL) was injected by autosampler. The gradient pro-
gram started at 30% B for 2 min, followed by an increase to 
95% B over 80 min. After separation, the column was iso-
cratic at 95% B for 15 min and then re-equilibrated with ini-
tial conditions for 15 min prior to next injection. Column 
temperature was 50°C and the flow rate was constant at 1 
mL/min. The HPLC system consisted of Waters 2695 Sep-
arations module and 2475 fluorescent detector (Milford). 
The detector settings were 360 nm excitation, 425 nm emis-
sion wavelength, and 20 nm bandwidth.
2.7 ESI-IT MS/MS analysis of N-glycans
MS analysis was performed on a 4000 Q-Trap hybrid tri-
ple quadruple/IT system (Applied Biosystems, Foster City, 
CA) with a MicroIon Spray II ion source. Approximately 
30~50 pmol/μL of N-glycans was prepared in 50% metha-
nol with 10 mM ammonium nitrate for negative ion mode. 
The sample solution was infused using a nanoflow Pico-
tip emitter (Uncoated SilicaTip, 360 μm od/15 μm id, New 
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Objectives, Woburn, MA) at 0.5 μL/min. Source and inlet 
conditions were as follows: curtain gas = 20, collision gas 
= high, ion spray voltage = –2400 V, Gas 1 = 5, and inter-
face heater temperature = 150°C. The declustering potential 
(DP) was set at –90 V. For MS/MS mode, the collision en-
ergy (CE) was dependent on the analyte. The scan rate was 
set to 1000 amu/s for enhanced MS (EMS) (IT mode) and 
enhanced product ion (EPI) scans, and 250 amu/s for en-
hanced resolution (ER) scan. For EMS, the linear IT (LIT) 
fill time was 100 ms with Q0 trapping activated. In EPI, Q1 
was set to low resolution, with Q0 trapping activated, and 
an LIT fill time of 400 ms.
Information-dependent acquisition (IDA) was also 
used for data collection from underivatized N-glycan 
samples. Survey scans (MS) were performed in EMS, fol-
lowed by ER of the four most intense peaks. Then, MS/
MS spectra were taken on these four peaks. IDA criteria 
were set as follows: select 1-4 most intense peaks, include 
charge states 1-4 plus unknowns; ER was used to con-
firm charge state, and former target ions were excluded 
after one occurrence for 60 s. Tentative structures identi-
fied from MS spectra were based on matches with glycans 
from the GlycoMod database.
2.8 Glycopeptide preparation
Glycoprotein was reduced and alkylated prior to proteo-
lytic digestion. Briefly, glycoprotein in 50 mM ammonium 
bicarbonate was mixed with DTT to make 5 mM final con-
centration and incubated at 60°C for 1 h. After cooling on 
ice, iodoacetamide was added to a final concentration of 
10 mM and then the sample was incubated at room tem-
perature in the dark for 30 min. The reduced and alkyl-
ated glycoprotein was incubated with PNGase F in 97 
atom % H2
18O or regular water at 37°C overnight. The de-
glycosylated peptide was digested with GluC (1:20 = en-
zyme:substrate w/w) at 25°C for 12 h and then with LysC 
(1:20 = Enzyme:substrate w/w) at 30°C for 12 h to gener-
ate VSFL(D)97CSLDNGGCTHYCLEE and IPVVPH(D)329E. 
EVFVHP(D)248YSK and R(D)313RTFVLNFIK were obtained 
by digestion with LysC (1:20 = enzyme:substrate mass ra-
tio) at 30°C for 12 h. The PNGase F digestion step was omit-
ted to obtain glycosylated peptides. The reactions were 
quenched with 1% v/v formic acid to yield a final 0.1% v/
v solution.
2.9 LC-ESI-IT MS/MS analysis of glycopeptides
The peptides were loaded onto an Acclaim PepMap100 
column (C18, 3 μm, 75 μm id × 150 mm, Dionex) using an 
UltiMate 3000 LC system (Dionex, Sunnyvale, CA) at 300 
nL/ min. Solvent A was 0.1% v/v formic acid in water 
and Solvent B was 0.1% v/v formic acid in ACN. Solvent 
B was held at 5% for 5 min, increased to 25% over 80 min 
and then increased to 95% over 5 min, and held at 95% for 
10 min. The column was re-equilibrated for 10 min prior 
to next run. The eluted samples were continuously in-
fused into a 4000 Q-Trap hybrid triple quadruple/IT mass 
spectrometer. 
For quantitation of the Asn-329 site occupancy, isotopi-
cally labeled internal peptide standards were designed as 
described in Hulsmeier et al. [26]. We observed that the ion-
ization efficiency of IPVVPHNE was 30–40% higher than 
IPVVPHDE. Therefore, as Hulsmeier et al. [26] discussed, 
isotopically labeled internal standards for both forms of a 
glycopeptide are best for accurate absolute quantification 
of site occupancy. Isotopically labeled amino acids are in 
bold and underlined, and the N-glycan sites in the peptide 
sequences are in parentheses in the text and figures. Two 
Pro of the peptide IPVVPH(N)E (+ 12.03 Da) and one Pro 
of IPVVPH(D)E (+ 6.01) were isotopically labeled to im-
prove the distinction between the internal standards and 
the corresponding sample peptides. The deglycosylated 
sample peptides bearing Asp were also labeled with 18O by 
digesting the glycoprotein with PNGase F in an H2
18O buf-
fer as described earlier. Therefore, a 2.99-Da mass differ-
ence was obtained between the sample peptides containing 
a converted Asp vs. an unoccupied Asn. The multiple reac-
tion monitoring (MRM) transition on the 4000 QTrap was 
used for the quantitation with Q1 and Q3 set at low reso-
lution. The transition parameters and CE are given in Ta-
ble 1 and were selected based on maximal signal intensities 
as judged from the MS/MS spectra of the peptides bearing 
Asp-329 (see Figure 5). The dwell time for each MRM tran-
sition was set to 100 ms. An equal amount (3 pmol each) 
of isotopically labeled standard peptide pairs was spiked 
into the samples prior to analysis. The peaks correspond-
ing to Q1/Q3 MRM transition were integrated using Ana-
lyst quantitation software (Applied Biosystems). The sam-
ple peptide amount was calculated by dividing the sample 
peak area by the corresponding standard peak area, and 
Table 1. MRM transition settings for the standard and sample peptides used for analysis of Asn-329 occupancy of hPC and tg-PC. Isotopically 
labeled Pro-P (+6.01 Da) and Asp-D (+2.00 Da) are bold and underlined, and the parentheses indicate the N-glycan sites.
Type  Sequence  Q1 [M+2H]2+ [m/z]  Q3[M+H]1 [m/z]  Q3 ion  CE [V]
Sample  IPVVPH(N)E  452.74  496.20  y4  35
Standard  IPVVPH(N)E  458.74  502.20  y4  40
Sample  IPVVPH(D)E  454.24  499.20  y4  35
Standard  IPVVPH(D)E  456.23  503.20  y4  40
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multiplying with the standard peptide amount added. 
The N-glycan site occupancy at Asn-329 is the percentage 
of the amount of sample peptide IPVVPH(D)E among the 
summed amount of the two peptides IPVVPH(N)E and 
IPVVPH(D)E. 
For the analysis of glycosylated peptides, precursor ion 
scans were performed for the product ion m/z 204.1. Source 
and inlet conditions were as follows: curtain gas = 20, col-
lision gas = high, ion spray voltage = 4200 V, Gas 1 = 25, 
DP = 65 V, CE= 45 V, and interface heater temperature = 
150°C. The scan rate was set to 250 amu/s for ER and 1000 
amu/s for EPI. The resolution for Q1 and Q3 was set to low 
and dynamic fill time was used. The MRM analysis was 
also performed for relative quantitation of glycopeptides 
at each N-glycan site. Transition parameters were the m/z 
of glycopeptide precursor ions for Q1, 204.1 (HexNAc) for 
Q3, 40 for CE, and 100 ms for dwell time. The peaks corre-
sponding to Q1/Q3 MRM transition were integrated using 
Analyst quantitation software. The source and gas condi-
tions were the same as above.
3 Results and discussion
N-glycan structures and the micro-heterogeneity at each 
N-glycan site of a commercially available plasma-derived 
hPC and the recombinant version from transgenic animals 
were investigated. MRM analysis was performed to quan-
tify site occupancy at Asn-329 and compared with previ-
ously published studies that used SDS-PAGE [6–8]. These 
studies were the basis for N-glycosylation analysis for two 
transgenic animals, denoted as 110-1 and 110-3, which were 
founder animals that contained a genomic hPC transgene 
construct with a 2.6-kb mouse whey acid protein (mWAP) 
promoter. The average tg-PC expression levels over the 
course of lactation appeared to be copy-number dependent 
for these animals: 100–300 mg/L for 110-1, and 1000–1600 
mg/L for 110-3 [27], representing a variation of expression 
approaching tenfold. We sought to determine if differences 
in N-glycan attachment and processing (especially at Asn-
329) were present in the transgenic animal bioreactor in 
this range of expression levels.
3.1 Sialic acid content of hPC and tg-PC
The first level of analysis was to quantify the type and 
amount of sialylation in the samples. Sialic acids were an-
alyzed by RP-HPLC using the method described in Anu-
mula et al. [24]. As summarized in Table 2, only N-acetyl-
neuraminic acid (Neu5Ac) was detected in both hPC and 
tg-PC. N-glycolylneuraminic acid (Neu5Gc) was below 
the lower limit of the quantitation (0.05 mol/mol pro-
tein C). Total Neu5Ac content of hPC was 50–80% higher 
than tg-PC, which may mean that the N-glycans of hPC 
are more highly branched and/or have more complete si-
alylation than tg-PC. The amount of sialylation in the tg-
PC samples does not appear to be rate limiting within this 
expression level range. We also found no Neu5Gc incor-
poration in the N-glycans of tg-FIX expressed in the milk 
of transgenic pigs [23]. These results indicate that the por-
cine mammary epithelial cells may glycosylate with only 
Neu5Ac termination, although the pig processes N-gly-
cans containing both Neu5Ac and Neu5Gc in other tis-
sues such as submandibular gland, lymph node, small in-
testine, spleen, and thymus [28].
3.2 NP-HPLC profiling of 2-AA-derivatized N-glycans
A “fingerprint” of the N-glycan structures was obtained 
by releasing the glycans with PNGase F, derivatizing with 
the fluorescent label 2-AA, and then separating with NP-
HPLC as described in Anumula and Dhume (1998) [25], in 
which AA-derivatized oligosaccharides can be separated 
based on size, charge, linkage, and overall structure. The 
well-characterized glycoprotein, bovine fetuin, is used as 
a standard in assignment of N-glycan separation based 
on the number of sialic acid moieties. The separated N-
glycans of bovine fetuin are grouped as 0S for neutral, 1S 
for mono-, 2S for di-, 3S for tri-, and 4S for tetra-sialylated 
oligosaccharides (Figure 1A). Figures 1B–D show that N-
glycans of hPC are di- or tri-sialylated structures, while 
tg-PC contains primarily mono- and di-sialylated oligo-
saccharides. Sialylated N-glycans of both hPC and tg-PC 
are more than 98% of total the N-glycan population, based 
on relative peak area integration from the chromatograms 
(Table 2). 
Table 2. Sialic acid content and percentages of sialylated glycan of hPC and tg-PC a
                    Expression Neu5Ac  Neu5Gc  % of   % of total  
 level  [mol/mol [mol/mol disialylated  sialylated 
                      [mg/L]   protein]b  protein]  glycan c  glycan c
hPC  –  7.4 ± 0.3  ND  87  99
tg-PC [pig 110-3]  1000~1600  4.9 ± 0.2  ND  12  99
tg-PC [pig 110-1]  100~300  4.1 ± 0.4  ND  7  98
a) Concentration of PC samples was obtained by measuring OD280nm using an extinction coefficient of 1.45 mL/mg-cm [1]. ND = not 
detectable. 
b) Molar ratio of Neu5Ac to Protein C was calculated from RP-HPLC analysis of sialic acid (run in triplicate). 
c) Percentages were obtained from NP-HPLC profiles. 
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3.3 N-glycan structures of hPC and tg-PC 
Structural analysis of the sialylated N-glycans was per-
formed by ESI-MS/MS IT analysis in negative mode (Figure 
2). The tentative structures of the ions from N-glycan MS 
profiles of hPC and tg-PC were proposed by searching Gly-
coMod ( http://ca.expasy.org/tools/glycomod ) and our 
own databases of N-glycan structures, and then assigned 
after inspecting the MS/MS spectra (Figure 3). HPC glycans 
are denoted as H1, H2, H3, etc., and tg-PC glycans are de-
noted as T1, T2, T3, etc. and are summarized in Figure 4.
The ESI-MS profile of hPC is given in Figure 2A. The 
ions at m/z 1110 [M-2H]2–, m/z 1183 [M-2H]2–, and m/z 1204 
[M- 2H]2–  found on hPC were assigned as di-sialylated bi-
antennary structures without and with core fucosylation, 
respectively. Peaks consistent with tri-sialylated trianten-
nary structures were also found at m/z 1438 [M-2H]2– and 
1511 [M- 2H]2– (MS/MS data not shown).
Figures 2B and C show MS spectra of tg-PC N-gly-
cans from pig 110-3 and 110-1, respectively, with struc-
ture identifications that were determined from MS/MS 
analysis. Representative MS/MS spectra are given in Fig-
ure 3. The doubly charged ions in the MS spectra are a 
mix of deprotonated species and nitrate adducts, because 
ammonium nitrate was used as an ion pairing reagent to 
improve sensitivity. The m/z 1971 [M-H]– peak is identi-
fied as a monosialylated biantennary with Gal and Gal-
NAc residues on each antennae (Figure 3A). The ion m/
z 424 indicates Hex + HexNAc + 59 as described in Har-
vey 2005 [29] and can be 1,3A4Y6 or 1,3A5Y5. The fragment 
ion B3 (m/z 655) indicates Neu5Ac + Hex + HexNAc se-
quence, and B3β  (m/z 696) indicates Neu5Ac + HexNAc + 
HexNAc, reflecting there are possible isomers according 
to the location of Neu5Ac termination. The same struc-
ture with a fucosylation is obtained from the m/z 2117 
[M-H]– precursor ion (Figure 3B). The core fucosylation 
can be deduced from the 146-Da difference between the 
fragment ion 0,2A7 from Figure 3A (m/z 1870) and Figure 
3B (m/z 2016). Figure 3C shows the MS/MS spectrum of 
a monosialylated biantennary glycan with two fucosyl-
ations. The fragment ions, 2,4A7 (m/z 1915) and 0,2A7 (m/
z 2121) were 146 Da higher than the corresponding ions, 
2,4A7 (m/z 1769) and 0,2A7 (m/z 1975) found in the MS/MS 
spectrum of a monosialylated biantennary glycan with a 
core fucosylation (data not shown), indicating that the N-
glycan structure in Figure 3C contains a core fucosylation 
and a fucosylation on the antennae. The position of this 
fucosylation could not be confirmed from our data. MS/
MS spectra of the other molecular ions were interpreted 
to assign the N-glycan structures and were the same as 
we found in our previous report of tg-FIX [23].
As summarized in Figure 4, the N-glycans of both hPC 
and tg-PC are bi- or tri-antennary complex structures. Ev-
idence for high-mannose and hybrid structures was not 
found, and we were also unable to find evidence for N-gly-
can structures terminated with Neu5Gc or -Gal for both 
hPC and tg-PC. The N-glycans of hPC are less heteroge-
neous than those of tg-PC, but more highly branched and 
more fully sialylated, which is consistent with sialic acid 
content analysis and NPHPLC profiles. 
Figure 1. HPLC N-glycan profiles of (A) bovine fetuin standard, (B) hPC, (C) tg-PC [110–3], and (D) tg-PC [110–1]. The separated N-gly-
cans of bovine fetuin are grouped as 0S for neutral, 1S for mono-, 2S for di-, 3S for tri-, and 4S for tetra-sialylated oligosaccharides as shown in 
panel (A).
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3.4 Macroheterogeneity: N-glycan site occupancy in hPC and 
tg-PC
Protein C contains the atypical Asn-X-Cys sequon. Analysis 
by SDS-PAGE and Western blot techniques estimated a 70– 
80% occupancy of Asn-329 in hPC [6–8]. One objective of 
this study was to analyze site occupancy at Asn-329 using 
current technology (MS/MS quantitation) and determine 
how efficiently this sequon is glycosylated in both hPC 
and tg-PC. The proteins were deglycosylated with PNGase 
F in an H2
18O buffer prior to proteolysis, which converts 
a glycosylated Asn to Asp (2.99-Da increase), and leaves 
Figure 2. MS spectra of N-glycans 
released from (A) hPC, (B) tg-PC 
[110-3], and (C) tg-PC [110-1]. 
HPC glycans are denoted as H1, 
H2, H3, etc., and tg-PC glycans are 
denoted as T1, T2, T3, etc. The N-
glycan structures of H1 ~ 5 and T1 
~ 13 are summarized in Figure 4.
Figure 3. MS/MS spectra of tg-
PC 110-3 N-glycan precursor 
ions (A) m/z [M-H]– 1971, (B) m/
z [M-H]– 2117, and (C) m/z [M-
H]– 2222. Key to symbols: ▼= fu-
cose; = ● mannose; = ○ galac-
tose; ■ = GlcNAc; □ = GalNAc; ♦ 
= Neu5Ac.


























unglycosylated Asn unchanged. We were able to detect 
only the peptides containing 18O-labeled Asp residues in 
the peptides containing Asn-97, 248, and 313 for both hPC 
and tg-PC (data not shown). These data indicate that these 
N-glycan sites of hPC and tg-PC are fully occupied. How-
ever, the peptides containing Asn-329 from both hPC and 
tg-PC had peptides bearing 18O-labeled Asp or Asn, indi-
cating the N-glycan site is partially occupied, and consis-
tent with previous reports [6–8]. 
For quantitation of the Asn-329 site occupancy, MRM 
analysis was performed with the addition of isotopically la-
beled peptide standards as described in the experimental 
section. The parameters for MRM transition were selected 
empirically based on maximal signal intensities as judged 
from the MS/MS spectra of the peptides bearing Asn-329 or 
Asp-329 (Figure 5). The most intense fragment ion, y4 was se-
lected for Q3, and the corresponding Q1 and Q3 m/z, and CE 
for the sample and standard peptides are listed in Table 1. 
Figure 6 shows the extracted ion chromatogram (XIC) 
of the MRM transitions of unglycosylated and deglycosyl-
ated sample peptides containing Asn-329 of hPC and tg-
PC, along with the internal standards. The peptide con-
taining the unoccupied Asn elutes earlier than the peptide 
having Asp. The average XIC peak areas of the peptides 
were used to calculate the site occupancy at Asn-329. As 
Figure 4. The identified N-glycan structures of hPC (H1 ~ 5) and 
tg-PC (T1 ~ 13). Keys to symbols are the same as Figure 3. 
Figure 5. MS/MS spectra of (A) 
the sample peptide IPVVPH(N)E, 
(B) the isotopically labeled stan-
dard peptide IPVVPH(N)E, (C) 
the sample peptide IPVVPH(D)E, 
which is labeled with 18O during 
PNGase F digestion, and (D) the 
isotopically labeled standard pep-
tide IPVVPH(D)E. Isotopically la-
beled Pro-P (+6.01 Da) and Asp-D 
(+2.00 Da) are bold and under-
lined, and the parentheses indicate 
the N-glycosylation sites. 
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summarized in Table 3, the site occupancy at Asn-329 for 
hPC is 78%, which is within the range of the previous re-
ports showing 70–80% occupancy [6–8]. There was no 
significant difference of the site occupancy between hPC 
(78%) and tg-PC (74–77%), indicating that the Asn-X-Cys 
sequon is recognized by the oligosaccharyl transferase 
complex of the porcine mammary epithelial cells with the 
same efficiency as that observed in human hepatocytes. 
We did not observe a decrease in N-glycan site occupancy 
of the high expressor 110-3 (77.0 ± 1.3%) vs. the low ex-
pressor 110-1 (74.3 ± 0.9%), indicating that attachment of 
the dolichol-oligosaccharide precursor in the ER at this 
Asn-X-Cys sequon is not a rate limiting step in this range 
of expression levels. Giuffrida et al. [12] reported that only 
1% of the human alpha-lactalbumin Asn-X-Cys sequon 
is occupied. From these results, it appears that site occu-
pancy of the Asn-X-Cys sequon in milk proteins is pro-
tein specific (as it appears to be for proteins synthesized 
in other tissues), and the capacity for filling these sites in 
the mammary epithelial cells (at least in the pig) can be 
very high.
3.5 Micro-heterogeneity of hPC and tg-PC
Another objective of this work was to evaluate the micro-
heterogeneity of both hPC and tg-PC, and to determine if 
there is any bias as to what glycan structures are found at 
a particular Asn residue, particularly Asn-329. Glycopep-
tides containing each N-glycan site were analyzed by LC-
MS/MS. The glycosylated peptides were detected using a 
precursor ion scan IDA method (m/z 204.1, HexNAc), and 
identity was confirmed by analysis of MS/MS spectra. 
Representative MS/MS spectra of glycosylated peptides 
from hPC and tg-PC are shown in Figure 7. The presence of 
N-glycan was confirmed by oxonium ions observed at m/
z 204 (HexNAc), 292 (Neu5Ac), 366 (Hex + HexNAc), 454 
(Neu5Ac + Hex), and 657 (Neu5Ac + Hex + HexNAc) in 
the spectra of glycopeptides. In this manner, the acquired 
spectra were searched for all possible glycopeptides bear-
ing the identified N-glycan structures for the four N-glyco-
sylation sites.
The relative amounts of the glycopeptides were com-
pared for each N-glycan site using MRM analysis of all iden-
Figure 6. Extracted ion chromatograms (XIC) of the MRM transitions of the Asn-329 glycopeptides from (A) hPC, (B) tg-PC 110-3, and (C) tg-
PC 110-1. Isotopically labeled Pro-P (+6.01 Da) and Asp-D (+2.00 Da) are bold and underlined, and the parentheses indicate the N-glycan sites. 
Table 3. N-glycan site occupancy of hPC and tg-PC
                                             Occupancy (%)
N-glycan site Peptide sequence  Protease used  hPC  tg-PC [110-3]  tg-PC [110-1]
Asn-97  VSFL(N)aCSLDNGGCTHYCLEE  GluC+LysC  Full  Full  Full
Asn-248  EVFVHP(N)YSK  LysC  Full  Full  Full
Asn-313  R(N)RTFVLNFIK  LysC  Full  Full  Full
Asn-329  IPVVPH(N)E  GluC+LysC  78.4 ±0.5b  77.0 ±1.3b  74.3 ±0.9b
a) The parentheses indicate the N-glycan sites. 
b) The data are from the average of triplicate digests and duplicate injections. 
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tified glycopeptides. It is understood that the sialic acid con-
tent can affect the ionization efficiency of a glycopeptide, 
and so our results are not strictly quantitative, but represent 
a first-order estimate of the micro-heterogeneity at each site. 
It has been shown that glycan processing is a function of pro-
tein folding, and can be influenced by glycosylation at other 
sites [30], but the mechanisms responsible have not been de-
termined. Our results for hPC showed that there was a dis-
tinct bias for particular N-glycan structures at each Asn resi-
due (Figure 8A). Asn-97 contained a more even distribution 
of glycan structures than other sites, with the predominant 
being the fucosylated triantennary sialylated species H5. 
Asn-248 was glycosylated predominantly with the bianten-
nary sialylated species H1 (not fucosylated), and contained 
lower amounts of fucosylated glycans H2, H3, and H5. Asn-
313 was predominantly glycosylated with the tri-antennary 
sialylated species H4 (non-fucosylated), and had low lev-
els of fucosylation at this site. Asn-329 was largely glycosyl-
ated with the fucosylated biantennary sialylated species H3, 
which contains GalNAc in one of the antennae.
The microheterogeneity of tg-PC from the two expres-
sion levels is summarized in Figures 8B and 8C. At Asn-
97 and Asn-248, the biantennary monosialylated T1 and 
T3 (fucosylated) species were predominant, with no clear 
preference for fucosylation. At Asn-313, both animals had a 
significant amount of species T2, which has GalNAc in one 
antennae, in addition to the T1 and T3 species. At Asn-329, 
the majority of the MRM signal was due to glycans which 
has a GalNAc in one antenna (T4, T9, and T11), although 
there was also a presence (~15–25% of peak areas) from the 
T1 species. Although some animal-to-animal variation in 
glycosylation is to be expected and is observed, these fea-
tures are consistent for both animals with high and low 
expression levels. Consistent with the NP-HPLC profile 
data, we do not see gross differences in glycan structures 
between the animals, and the distribution of glycan struc-
tures at each Asn residue is similar. Thus, we can conclude 
that a tenfold difference in expression level does not affect 
N-glycan processing at each of the four sites.
One interesting feature of the microheterogeneity anal-
ysis is that for both hPC and tg-PC, glycans with GalNAc 
in the antennae (H3 for hPC and T4, T9, T11 for tg-PC) 
were more abundant at Asn-329 than at Asn-97, 248, and 
313. The reason for this is not known at this time. Sato et al. 
[15] reviewed the structures found at Asn-X-Cys sequons 
in other proteins, and there does not appear to be any spe-
cific inter-protein bias for glycan processing at Asn-X-Cys 
sequons. For the case of hPC and tg-PC, it may be that the 
GalNAc transferase has more access to the nascent glycan 
at Asn-329 than the other locations. 
Figure 7. MS/MS spectra of hPC 
glycopeptides (A) VSFL(N)97- 
CSLDNGGCTHYCLEE and (B) 
EVFVHP(N)248YSK bearing the H1 
N-glycan structure, and tg-PC gly-
copeptides (C) R(N)313RTFVLNFIK 
and (D) IPVVPH(N)329E bearing the 
T1 N-glycan structure. H1 and T1 
structures are shown in Figure 4.
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4 Concluding remarks
The N-glycans of hPC are complex di- and tri-sialylated 
structures, and MRM analysis resulted in a measured 78% 
site occupancy at Asn-329, which agrees with previous re-
ports that used SDS-PAGE methods. We analyzed the mi-
croheterogeneity of hPC N-glycosylation, and found that 
there was a distinct bias for particular structures being 
present at each of the four sites, and that glycans with Gal-
NAc in the antennae were predominant at the Asn-329 site. 
We compared hPC N-glycosylation with a recombinant 
protein C produced in the milk of transgenic animals hav-
ing expression levels that ranged from about 100–1600 mg/
L. The N-glycans of tg-PC were complex sialylated struc-
tures (with Neu5Ac only), but were less branched and par-
tially sialylated. The porcine mammary epithelial cells gly-
cosylate the Asn-X-Cys sequon with a similar efficiency as 
human hepatocytes, and the extent of site occupancy at this 
sequon was not affected by a ten-fold difference in expres-
sion level. Thus, the mammary epithelial cells have a very 
high capacity for glycosylation of Asn-X-Cys sequons. We 
have also shown that this range of expression level does 
not significantly affect the tg-PC N-glycan structures at 
each site: N-glycan processing in the Golgi is not rate limit-
ing. Similar to hPC, we found that glycans with GalNAc in 
the antennae were predominant at Asn-329. The reason for 
this is not understood at this time, but it appears to be spe-
cific for protein C, and not a general feature of glycans at 
the Asn-X-Cys sequon. 
We found that the tg-PC N-glycan structures were very 
similar to those found in the analysis of tg-FIX [23] and en-
dogenous lactoferrin [31], and thus we have three cases 
of porcine mammary epithelial cells processing glycopro-
teins at gram/liter/hour expression levels with similar N-
glycan structures. This is in contrast to N-glycosylation of 
hPC and human Factor IX (hFIX) by hepatocytes. HFIX is 
homologous to hPC: both are vitamin K-dependent gly-
coproteins that are synthesized in hepatocytes, and they 
Figure 8. Percentage of glycopeptide peak 
area at each N-glycan site of (A) hPC, (B) 
tg-PC 110-3, and (C) tg-PC 110-1. Peak areas 
were obtained from MRM analysis of all de-
tectable glycopeptides. The N-glycan struc-
tures of H1 ~ 5 and T1 ~13 on the x-axis are 
summarized in Figure 4.
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are homologous with respect to amino acid sequence, do-
main structure, and function (both are serine proteases). 
HFIX has two N-glycosylation sites [32] and significantly 
more heterogeneity of N-glycan structures than we have 
found for hPC. Since both hPC and hFIX are synthesized 
and secreted by hepatocytes, where the N-glycan biosyn-
thesis and processing pathways should be the same for 
both proteins, one could hypothesize that the folding of 
the glycoprotein substrate plays an important role on N-
glycan processing in human hepatocyte Golgi. However, 
the data clearly show that this hypothesis cannot be ex-
trapolated to tg-PC and tg-FIX; the N-glycans of tg-PC are 
very similar to those found for tg-FIX with respect to both 
the level of sialylation and the structures [23]. The reason 
for this is not known at this time. It could be that in the 
porcine mammary epithelial Golgi, recombinant proteins 
are not folded to the extent that they are in human hepato-
cytes, and thus the glycosidases and glycosyltransferases 
see more uniform substrates. The glycosidases and glyco-
syltransferases present in the porcine mammary epithelial 
cells could also be inherently less sensitive to the nascent 
protein structure. In addition, fewer processing enzymes 
may be present in the mammary epithelial cells during lac-
tation. Whatever the cause, these results indicate that the 
N-glycosylation machinery of porcine mammary epithe-
lial cell is consistent with respect to the N-glycan process-
ing of two different recombinant glycoproteins, and con-
sistent with respect to a previously reported endogenous 
milk glycoprotein.
Acknowledgments
This work was supported by a grant from the National Heart, 
Lung, and Blood Institute (R01 HL078944-01) and by the Uni-
versity of Nebraska.
Conflict of interest statement
W. H. Velander is a co-founder and stockholder in Progenetics 
LLC, a company that develops transgenic animal bioreactors 
for production of therapeutic proteins.
5 References
[1] Kisiel, W., Human plasma protein C: isolation, characterization, 
and mechanism of activation by alpha-thrombin. J. Clin. Invest. 
1979, 64, 761–769. 
[2] Esmon, C. T., The regulation of natural anticoagulant pathways. Sci-
ence 1987, 235, 1348–1352. 
[3] McClure, D. B., Walls, J. D., Grinnell, B. W., Post-translational pro-
cessing events in the secretion pathway of human protein C, 
a complex vitamin K-dependent antithrombotic factor. J. Biol. 
Chem. 1992, 267, 19710–19717. 
[4] Grinnell, B. W., Walls, J. D., Gerlitz, B., Berg, D. T. Native and Mod-
ified Recombinant Human Protein C: Function, Secretion, and Post-
translational Modifications, Gulf Publishing Company, Houston, 
TX 1990. 
[5] Stenflo, J., Fernlund, P., Amino acid sequence of the heavy chain of 
bovine protein C. J. Biol. Chem. 1982, 257, 12180–12190. 
[6] Grinnell, B. W., Berg, D. T., Walls, J., Yan, S. B., Trans-activated expres-
sion of fully gamma-carboxylated recombinant human protein 
C, an antithrombotic factor. Bio/Technol. 1987, 5, 1189–1192. 
[7] Grinnell, B. W., Walls, J. D., Gerlitz, B., Glycosylation of human pro-
tein C affects its secretion, processing, functional activities, and 
activation by thrombin. J. Biol. Chem. 1991, 266, 9778–9785. 
[8] Miletich, J. P., Broze, G. J. J., Beta protein C is not glycosylated at 
asparagine 329. The rate of translation may influence the fre-
quency of usage at asparagine-X-cysteine sites. J. Biol. Chem. 
1990, 265, 11397–11404. 
[9] Araki, T., Haupt, H., Hermentin, P., Schwick, H. G. et al., Preparation 
and partial structural characterization of alpha1T-glycoprotein 
from normal human plasma. Arch. Biochem. Biophys. 1998, 351, 
250–256. 
[10] Titani, K., Kumar, S., Takio, K., Ericsson, L. H. et al., Amino acid se-
quence of human von Willebrand factor. Biochemistry 1986, 25, 
3171–3184. 
[11] Vance, B. A., Wu, W., Ribaudo, R. K., Segal, D. M., Kearse, K. P., 
Multiple dimeric forms of human CD69 result from differen-
tial addition of N-glycans to typical (Asn-X-Ser/Thr) and atyp-
ical (Asn-X-Cys) glycosylation motifs. J. Biol. Chem. 1997, 272, 
23117–23122. 
[12] Giuffrida, M. G., Cavaletto, M., Giunta, C., Neuteboom, B. et al., 
The unusual amino acid triplet Asn-lle-Cys is a glycosylation 
consensus site in human -lactalbumin. J. Protein Chem. 1997, 16, 
747–753. 
[13] Krogh, T. N., Bachmann, E., Teisner, B., Skjodt, K., Hojrup, P., Gly-
cosylation analysis and protein structure determination of mu-
rine fetal antigen 1 (mFAl). Eur. J. Biochem. 1997, 244, 334–342. 
[14] Jensen, C. H., Krogh, T. N., Hojrup, P., Clausen, P. P. et al., Pro-
tein structure of fetal antigen 1 (FA1). Eur. J. Biochem. 1994, 225, 
83–92. 
[15] Sato, C., Kim, J.-H., Abe, Y., Saito, K. et al., Characterization of 
the N-oligosaccharides attached to the atypical Asn-X-Cys se-
quence of recombinant human epidermal growth factor recep-
tor. J. Biochem. 2000, 127, 65–72. 
[16] Jackson, C. V., Bailey, B. D., Shetler, T. J., Pharmacological profile of 
recombinant, human activated protein C (LY203638) in a canine 
model of coronary artery thrombosis. J. Pharmacol. Exp. Ther. 
2000, 295, 967–971. 
[17] Macias, W. L., Yan, S. B., Grinnell, B. W., The development of 
drotrecogin alfa (activated) for the treatment of severe sepsis. 
Int. J. Artif. Organs. 2004, 27, 360–370. 
[18] Macias, W. L., Dhainaut, J. F., Yan, S. C., Helterbrand, J. D. et al., 
Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa 
(activated) in patients with severe sepsis. Clin. Pharmacol. Ther. 
2002, 72, 391–402. 
[19] Yan, S. B., Chao, Y. B., van Halbeek, H., Novel Asn-linked oligo-
saccharides terminating in GalNAc beta (1–>4)[Fuc alpha (1–
>3)]GlcNAc beta (1–>.) are present in recombinant human 
n-GlyCosylation of asn-X-Cys sequon in prote in C   2567
protein C expressed in human kidney 293 cells. Glycobiology 
1993, 3, 597–608. 
[20] Lubon, H., Paleyanda, R. K., Velander, W. H., Drohan, W. N., Blood 
proteins from transgenic animal bioreactors. Transfus. Med. Rev. 
1996, 5, 131–143. 
[21] Van Cott, K. E., Williams, B., Velander, W. H., Gwazdauskas, F. et al., 
Affinity purification of biologically active and inactive forms of 
recombinant human protein C produced in porcine mammary 
gland. J. Mol. Recognit. 1996, 9, 407–414. 
[22] Velander, W. H., Johnson, J. L., Page, R. L., Russell, C. G. et al., High-
level expression of a heterologous protein in the milk of trans-
genic swine using the cDNA encoding human protein C. Proc. 
Natl. Acad. Sci. USA 1992, 89, 12003–12007. 
[23] Gil, G.-C., Velander, W. H., Van Cott, K. E., Analysis of the N-gly-
cans of recombinant human Factor IX purified from transgenic 
pig milk. Glycobiology 2008, 18, 526–539. 
[24] Anumula, K. R., Rapid quantitative determination of sialic acids 
in glycoproteins by high-performance liquid chromatography 
with a sensitive fluorescence detection. Anal. Biochem. 1995, 230, 
24–30. 
[25] Anumula, K. R., Dhume, S. T., High resolution and high sensitivity 
methods for oligosaccharide mapping and characterization by 
normal phase high performance liquid chromatography follow-
ing derivatization with highly fluorescent anthranilic acid. Glyco-
biology 1998, 8, 685–694. 
[26] Hulsmeier, A. J., Paesold-Burda, P., Hennet, T., N-glycosylation site 
occupancy in serum glycoproteins using multiple reaction mon-
itoring liquid chromatography-mass spectrometry. Mol. Cell. Pro-
teomics 2007, 6, 1031–1042. 
[27] Van Cott, K. E., Lubon, H., Russell, C. G., Butler, S. P et al., Pheno-
typic and genotypic stability of multiple lines of transgenic pigs 
expressing recombinant human protein C. Transgenic Res. 1997, 
6, 203–212. 
[28] Malykh, Y. N., Shaw, L., Schauer, R., The role of CMP-Nacetyl-
neuraminic acid hydroxylase in determining the level of N-gly-
colylneuraminic acid in porcine tissues. Glycoconj. J. 1998, 15, 
885–893. 
[29] Harvey, D. J., Fragmentation of negative Ions from carbohydrates: 
Part 3. fragmentation of hybrid and complex N-linked glycans. J. 
Am. Soc. Mass Spectrom. 2005, 16, 647– 659. 
[30] Wojczyk, B. S., Takahashi, N., Levy, M. T., Andrews, D. W. et al., N-
glycosylation at one rabies virus glycoprotein sequon influences 
N-glycan processing at a distant sequon on the same molecule. 
Glycobiology 2005, 15, 655–666. 
[31] Spik, G., Coddeville, B., Mazurier, J., Bourne, Y. et al., Primary and 
three-dimensional structure of lactotransferrin (lactoferrin) gly-
cans. Adv. Exp. Med. Biol. 1994, 357, 21–32. 
[32] Makino, Y., Omichi, K., Kuraya, N., Ogawa, H. et al., Structural 
analysis of N-linked sugar chains of human blood clotting Fac-
tor IX. J. Biochem. 2000, 128, 175–180.
